Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery, including several academic speakers.
|
8:00 AM - 8:45 AM
|
Registration and Coffee, Light Breakfast |
|
8:45 AM - 9:00 AM
|
Niels Fertig, Nanion Technologies
Welcome and Opening Remarks |
| |
Session I
Chair: David Dalrymple, SB Drug Discovery |
|
9:00 AM - 9:45 AM
|
Keynote Speaker: Professor William Colmers, University of Alberta
NPY, HCN1 and Stress Resilience
|
|
9:45 AM - 10:15 AM
|
Stephen Hess, Evotec AG
Use of Automated Patch Clamp Platforms to Support Ion Channel Drug Discovery
|
|
10:15 AM - 10:45 AM
|
Marc Rogers, Metrion Biosciences
Successful Development of State-dependent Voltage-gated Ion Channel Modulators with in vivo Efficacy Using Automated Patch Clamp Assays for Primary Target Potency, Species and Gene Family Selectivity, and Cardiac Safety
|
| 10:45 AM - 11:15 AM |
Coffee Break |
| |
Session II
Chair: Stephen Hess, Evotec AG |
| 11:15 AM - 11:45 AM |
Tianbo Li, Genentech
ProTx-II Inhibits Nav1.7 Through an Electrostatic Gating Modulation Mechanism |
| 11:45 AM - 12:15 PM |
Hongkang Zhang, Q-State Biosciences
Target Based Screening on Nav Channels in Spiking HEK Cells, Using Optical Stimulation and Recording |
| 12:15 PM - 12:45 PM |
David Dalrymple, SB Drug Discovery
Assessment of Diverse and Focused Libraries for GABA Receptor Screening |
| 12:45 PM - 1:45 PM |
Lunch |
| |
Session III
Chair: Marc Rogers, Metrion Biosciences |
| 1:45 PM - 2:30 PM |
Keynote Speaker: Professor Pancho Bezanilla, University of Chicago
Stimulating with Light |
| 2:30 PM – 3:00 PM |
James Ellis, Nocion Therapeutics
Novel Small Molecule Nav Channel Blockers Selectively Targeting Nociceptors for the Treatment of Cough, Pain and Itch |
| 3:00 PM - 3:30 PM |
Aneesh Karatt-Vellatt, Iontas
Knottin-antibody Fusion Proteins (KnotBodies): a Novel Biologics Class Targeting Kv1.3 (Autoimmunity), Nav1.7 (Chronic Pain) and ASIC1a (Stroke) |
| 3:30 PM - 4:00 PM |
Coffee Break |
| |
Session IV
Chair: James Ellis, Nocion Therapeutics |
| 4:00 PM – 4:30 PM |
Sam Goodchild, Xenon
Pharmacology of Voltage Sensor Targeting Nav1.6 Inhibitors |
| 4:30 PM - 5:00 PM |
Fern Toh, Alkermes, Inc.
Application of High-throughput Automated Patch-clamp Techniques to Study Ion Channel Function in Cultured Primary Rat Cortical and Hypothalamic Neurons |
| 5:00 PM |
Thomas Binzer, Sophion Bioscience
Closing Remarks |
Sponsored by:
